LAS VEGAS, Dec. 16, 2002 (PRIMEZONE) -- Coyote Ventures Corp. (OTCBB:CYTV) (the "Company") announces today that Dr. Christopher Thompson has been appointed Chair of the Company's Scientific Advisory Board, which will guide product development including the design of appropriate clinical trials, selection of clinical sites and partners, as well as providing advice with respect to regulatory approval of the Company's products.
Dr. Christopher Thompson received his Internal Medicine and Cardiology training at St. Paul's Hospital, University of British Columbia, Vancouver, and his Cardiology Research training at Foothills Hospital, University of Calgary in Alberta. Dr. Thompson was Director of Cardiology Research at St. Paul's Hospital from 1994 to 2001 evaluating new and emerging therapies, therapeutic strategies, and devices in cardiac patients. Also, Dr. Thompson is a Clinical Associate Professor, Division of Cardiology, Department of Medicine at the University of British Columbia; Director, Cardiac Echo Laboratory; and attending Cardiologist at St. Paul's Hospital. Dr. Thompson is a former member of both the scientific review committee of the Heart and Stroke Foundation of Canada and Heart and Stroke Foundation of British Columbia and the Yukon and will be an important addition to the firm.
Coyote Ventures Corp. and its subsidiaries are engaged in the research, development and commercialization of medical imaging technologies, which aids in the detection and localization of cancer.
Public Company Disclosure
This document may contain certain forward-looking statements regarding Coyote Ventures Inc. including statements about its operations, prospects and expectations about future financial results, including, but not limited to, future revenues and earnings. The words "estimate", "possible," "expects", "anticipates", "believes", "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. These forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially and are subject to change at any time. The Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including those risks and uncertainties detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2001 filed with the SEC as well as subsequent forms 8-Ks, 10-Qs, 14-C and S-8 registrations.